Medicare Part D beneficiaries who are denied coverage for a prescribed medication now have 65 calendar days to file a formal appeal with their plan, five days longer than the previous window. The Centers for Medicare & Medicaid Services (CMS) extended the filing deadline from 60 to 65 days effective January 1, 2025, updating standardized forms and notices across every level of the appeals process. That extra time may help some enrollees, but the real barriers to a successful challenge often start well before the clock begins ticking.
Why the 65-Day Filing Window Changed for 2025
When a Part D plan refuses to pay for a drug, it must send a standardized denial notice using the CMS-10146 form, which explains the reason for the refusal and spells out the enrollee’s appeal rights. The quality of that notice matters because the 65-day appeal clock starts on the date the plan issues it. CMS updated all official Part D appeal forms to reflect the new deadline, with the revised versions taking effect on January 1, 2025, according to the agency’s Part D appeals guidance.
The five-day extension addresses a narrow but real problem: enrollees who miss the old 60-day cutoff and have their appeals dismissed as untimely. Whether those extra days actually reduce dismissals depends on how clearly each plan communicates the denial in the first place. Plans that already send thorough, plainly worded notices give beneficiaries a head start. Plans whose notices are confusing or delayed effectively shrink the window regardless of its official length.
A separate, persistent obstacle sits outside the deadline question entirely. A Government Accountability Office report, GAO-08-47, found that Part D plans dismissed appeals when Appointment of Representative forms were incomplete, a paperwork failure that has nothing to do with how many days an enrollee has to file. For beneficiaries who rely on family members or advocates to act on their behalf, the extended deadline alone does not solve the documentation gap that trips up their cases at the first level of review.
How the Five-Level Appeal Ladder Works
Before filing an appeal, an enrollee or prescriber can request a coverage determination or exception from the plan using the standard request form, which asks for drug details, prescriber information, and clinical rationale. This is the step where a plan decides whether a drug will be covered, under what conditions, and at what cost-sharing level.
If the plan denies that request, the formal appeals process begins. At Level 1, the beneficiary or representative files a redetermination with the plan. The plan reviews its original decision, considers any new supporting information, and issues a written decision that starts the 65-day clock for the next stage if the denial is upheld.
Level 2 sends the case to an independent review entity for reconsideration. This contractor is separate from the plan and evaluates whether the denial complies with Medicare rules and the plan’s own coverage criteria. The reconsideration decision again triggers a 65-day period to move forward if the beneficiary remains dissatisfied.
The third level is an Administrative Law Judge hearing through the Office of Medicare Hearings and Appeals, available only if the amount remaining in controversy meets the annual threshold set by the Department of Health and Human Services. Hearings can be conducted by phone, video, or in writing, and beneficiaries may submit testimony or additional medical evidence.
After an ALJ decision, Level 4 review occurs at the Medicare Appeals Council, which examines whether the judge correctly applied Medicare law and policy. The final step, Level 5, is judicial review in federal district court, again subject to a minimum dollar amount in dispute. At each of these stages, strict timelines apply both to beneficiaries and to adjudicators, and missing a deadline can end the appeal unless “good cause” for late filing is established.
Practical Implications for Beneficiaries
The expanded 65-day filing window gives beneficiaries slightly more breathing room to gather medical records, consult with prescribers, and complete representation paperwork. However, the complexity of the process means that education and early action remain critical. CMS urges enrollees to review their plan materials and to use the official drug plan appeals instructions to understand how and when to challenge a denial.
Advocates say the most effective strategies still involve front-loading the case: ensuring the initial coverage determination request is complete, documenting clinical necessity in detail, and submitting a properly executed Appointment of Representative form when someone is assisting the beneficiary. The five extra days may prevent some appeals from being dismissed as late, but they do not replace the need for clear notices, accurate forms, and timely follow-through at every level of the Part D appeal ladder.
